CD40 and neoplasm: In a mouse model humanized both for Fc receptors and CD40, direct delivery of an Fc-engineered anti-CD40 agonistic antibody to the tumor site maintained antitumor activity, but with fewer platelet and hepatic toxicities compared to systemic administration [85].